Angiotensin II inhibits the A-type K + current of hypothalamic paraventricular nucleus neurons in rats with heart failure: role of MAPK-ERK1/2 signaling.

Autor: Roy RK; Neuroscience Institute, Georgia State University, Atlanta, Georgia., Ferreira-Neto HC; Neuroscience Institute, Georgia State University, Atlanta, Georgia., Felder RB; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa., Stern JE; Neuroscience Institute, Georgia State University, Atlanta, Georgia.
Jazyk: angličtina
Zdroj: American journal of physiology. Regulatory, integrative and comparative physiology [Am J Physiol Regul Integr Comp Physiol] 2022 Jun 01; Vol. 322 (6), pp. R526-R534. Date of Electronic Publication: 2022 Mar 23.
DOI: 10.1152/ajpregu.00308.2021
Abstrakt: Angiotensin II (ANG II)-mediated sympathohumoral activation constitutes a pathophysiological mechanism in heart failure (HF). Although the hypothalamic paraventricular nucleus (PVN) is a major site mediating ANG II effects in HF, the precise mechanisms by which ANG II influences sympathohumoral outflow from the PVN remain unknown. ANG II activates the ubiquitous intracellular MAPK signaling cascades, and recent studies revealed a key role for ERK1/2 MAPK signaling in ANG II-mediated sympathoexcitation in HF rats. Importantly, ERK1/2 was reported to inhibit the transient outward potassium current ( I A ) in hippocampal neurons. Given that I A is a critical determinant of the PVN neuronal excitability, and that downregulation of I A in the brain has been reported in cardiovascular disease states, including HF, we investigated here whether ANG II modulates I A in PVN neurons via the MAPK-ERK pathway, and, whether these effects are altered in HF rats. Patch-clamp recordings from identified magnocellular neurosecretory neurons (MNNs) and presympathetic (PS) PVN neurons revealed that ANG II inhibited I A in both PVN neuronal types, both in sham and HF rats. Importantly, ANG II effects were blocked by inhibiting MAPK-ERK signaling as well as by inhibiting epidermal growth factor receptor (EGFR), a gateway to MAPK-ERK signaling. Although no differences in basal I A magnitude were found between sham and HF rats under normal conditions, MAPK-ERK blockade resulted in significantly larger I A in both PVN neuronal types in HF rats. Taken together, our studies show that ANG II-induced ERK1/2 activity inhibits I A , an effect expected to increase the excitability of presympathetic and neuroendocrine PVN neurons, contributing in turn to the neurohumoral overactivity that promotes progression of the HF syndrome.
Databáze: MEDLINE